Hematologic Malignancy Biology Study
Laboratory-based investigations have contributed to an improved understanding of
pathophysiology and to the development of new therapies for hematologic malignancies.
The aim of this protocol is to facilitate biologic study of leukemias, myelodysplastic
syndromes, lymphomas, and other blood disorders.
This is a sample acquisition protocol for targeted study of hematologic malignancies by a
collaborative network of NIH investigators from multiple Institutes/Centers.
This biology protocol is designed to allow sample acquisition for use in the study of
hematologic malignancies. A variety of laboratory investigations designed to support NIH
translational trials; to apply new methodologies in the study of cellular, molecular,
genetic, and genomic biology; to probe for new therapeutic targets; and to develop new
treatment approaches will be performed.
Diagnosis of any hematologic malignancy or pre-malignant blood disorder, including but not
restricted to the following: Acute Lymphocytic Leukemia (ALL), Acute Myelogenous Leukemia
(AML), Myelodysplastic Syndrome (MDS), Chronic Myelogenous Leukemia (CML), Juvenile
Myelomonocytic Leukemia (JMML, J-CML), Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease
Tumor tissue that has been previously collected and is available for study or that can be
collected with minimal additional risk to the subject during sampling required for routine
Patient age: birth to 75 years.
Biologic assays relevant to the investigation of hematologic malignancies will be performed
in an exploratory fashion, some studies are developmental, i.e., assay design in support of
current or planned CC clinical trials. Others are standard assays that will be applied in
attempt to identify new targets or test new therapeutic approaches.
Alan S Wayne, M.D.
National Cancer Institute (NCI)
United States: Federal Government
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Bethesda, Maryland 20892|